Literature DB >> 30426535

Radiolabeling, quality control, biodistribution, and imaging studies of 177 Lu-ibandronate.

Qin Xu1,2, Shumao Zhang1,2, Yan Zhao1,2, Yue Feng1,2, Lin Liu1,2, Liang Cai1,3, Wei Zhang1,2, Zhanwen Huang1,2, Hongyuan Wei4,5, Liangang Zhuo4,5, Yue Chen1,2.   

Abstract

The purposes of this study were as follows: (1) to radiolabel ibandronic acid (IBA, a third-generation bisphosphonate) with 177 Lu, investigating optimal labeling conditions, and (2) to analyze biodistribution and imaging properties of intravenous 177 Lu-ibandronate (177 Lu-IBA) administered in animals. 177 Lu-labeled methylene diphosphonate (177 Lu-MDP) served as a comparator agent. Differing proportions of IBA solution and 177 LuCl3 solution were combined to determine an optimal ratio for radiolabeling purposes, varying pH, temperature, and time to establish ideal reactivity conditions. Radiochemical purity of the labeled compounds was then assessed by paper chromatography. In vitro and in vivo stabilities were also measured at specific time intervals. In Kunming mice, biodistributions of 177 Lu-IBA and 177 Lu-MDP and respective agent activities in various organs were monitored by gamma counter, and we performed single photon computed tomography/computed tomography (SPECT/CT) imaging of 177 Lu-IBA in normal New Zealand White rabbits. Radiolabeling yields for 177 Lu-IBA proved to be >97% within 30 minutes at 90°C, and its radiochemical purity ensured stability in vitro and in vivo. Furthermore, we found that 177 Lu-IBA is readily soluble in water, showing higher skeletal uptake than 177 Lu-MDP but lower uptake by liver and spleen. The image quality of 177 Lu-IBA was so clear that even after 6 days, analysis was still feasible.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  177Lu; biodistribution; bone imaging; ibandronic acid

Year:  2018        PMID: 30426535     DOI: 10.1002/jlcr.3694

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  1 in total

1.  Preparation, Characterization, and Preliminary Imaging Study of [188Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis.

Authors:  Tingting Xu; Yingwei Wang; Zan Chen; Hanxiang Liu; Songsong Yang; Guangfu Liu; Yan Zhao; Wenhui Fu; Lin Liu; Ke Xiang; Dengsai Peng; Yue Chen
Journal:  Contrast Media Mol Imaging       Date:  2022-02-25       Impact factor: 3.161

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.